NBTX vs. XNCR, ABCL, CDXC, KALV, REPL, BCYC, ANAB, COGT, VECT, and SION
Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Xencor (XNCR), AbCellera Biologics (ABCL), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Cogent Biosciences (COGT), VectivBio (VECT), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.
Nanobiotix vs.
Nanobiotix (NASDAQ:NBTX) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Nanobiotix presently has a consensus price target of $8.00, suggesting a potential upside of 113.05%. Xencor has a consensus price target of $29.50, suggesting a potential upside of 292.29%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Nanobiotix.
38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Nanobiotix has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Nanobiotix's return on equity of 0.00% beat Xencor's return on equity.
In the previous week, Xencor had 4 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Xencor and 3 mentions for Nanobiotix. Xencor's average media sentiment score of 0.52 beat Nanobiotix's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.
Nanobiotix has higher earnings, but lower revenue than Xencor.
Xencor received 497 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 73.13% of users gave Xencor an outperform vote while only 63.16% of users gave Nanobiotix an outperform vote.
Nanobiotix has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Summary
Xencor beats Nanobiotix on 12 of the 17 factors compared between the two stocks.
Get Nanobiotix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nanobiotix Competitors List
Related Companies and Tools
This page (NASDAQ:NBTX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy NBTX Stock Free NBTX Stock Alerts